Tags

Type your tag names separated by a space and hit enter

Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
Acta Ophthalmol 2017; 95(7):678-682AO

Abstract

PURPOSE

To evaluate the visual outcome after transitioning from a pro re nata (PRN) intravitreal injection regimen to a treat-and-extend (TAE) regimen for patients with neovascular age-related macular degeneration (AMD).

METHODS

A retrospective review of patients who were switched from a PRN regimen with intravitreal injections of bevacizumab, ranibizumab or aflibercept to a TAE regimen. The best corrected visual acuity (BCVA), central retinal thickness (CRT) and type of medication used at baseline, at the time of changing treatment regimen and at the end of the study were analysed.

RESULTS

Twenty-one eyes of 21 patients met the inclusion criteria. Prior to the switch, the patients received a mean of 13.8 injections (median, 10; range, 3-39 injections) with the PRN regimen for 44 months (range, 3-100 months), which improved the visual acuity in five patients (24%). After a mean of 6.1 injections (median, 5; range, 3-14 injections) with the TAE regimen over 8 months (range, 2-16 months), the visual acuity improved in 12 patients (57%). The improvement in visual acuity during treatment with the TAE regimen was statistically significant (p = 0.005). The proportion of patients with a visual acuity of 0.2 or better was significantly higher after treatment with the TAE regimen than after treatment with the PRN regimen (p = 0.048). No significant differences in CRT were found between the two treatment regimens.

CONCLUSION

Even after prolonged treatment and a high number of intravitreal injections, switching AMD patients from a PRN regimen to a strict TAE regimen significantly improves visual acuity.

Authors+Show Affiliations

Department of Ophthalmology, Haukeland University Hospital, Bergen, Norway. Department of Ophthalmology, Division Lillehammer, Innlandet Hospital Trust, Lillehammer, Norway.Department of Ophthalmology, Haukeland University Hospital, Bergen, Norway. Department of Clinical Medicine, Section of Ophthalmology, University of Bergen, Bergen, Norway.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28139082

Citation

Kvannli, Line, and Jørgen Krohn. "Switching From Pro Re Nata to Treat-and-extend Regimen Improves Visual Acuity in Patients With Neovascular Age-related Macular Degeneration." Acta Ophthalmologica, vol. 95, no. 7, 2017, pp. 678-682.
Kvannli L, Krohn J. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration. Acta Ophthalmol. 2017;95(7):678-682.
Kvannli, L., & Krohn, J. (2017). Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration. Acta Ophthalmologica, 95(7), pp. 678-682. doi:10.1111/aos.13356.
Kvannli L, Krohn J. Switching From Pro Re Nata to Treat-and-extend Regimen Improves Visual Acuity in Patients With Neovascular Age-related Macular Degeneration. Acta Ophthalmol. 2017;95(7):678-682. PubMed PMID: 28139082.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration. AU - Kvannli,Line, AU - Krohn,Jørgen, Y1 - 2017/01/31/ PY - 2016/01/17/received PY - 2016/11/05/accepted PY - 2017/2/1/pubmed PY - 2018/1/3/medline PY - 2017/2/1/entrez KW - age-related macular degeneration KW - anti-VEGF therapy KW - pro re nata KW - treat-and-extend KW - treat-and-observe SP - 678 EP - 682 JF - Acta ophthalmologica JO - Acta Ophthalmol VL - 95 IS - 7 N2 - PURPOSE: To evaluate the visual outcome after transitioning from a pro re nata (PRN) intravitreal injection regimen to a treat-and-extend (TAE) regimen for patients with neovascular age-related macular degeneration (AMD). METHODS: A retrospective review of patients who were switched from a PRN regimen with intravitreal injections of bevacizumab, ranibizumab or aflibercept to a TAE regimen. The best corrected visual acuity (BCVA), central retinal thickness (CRT) and type of medication used at baseline, at the time of changing treatment regimen and at the end of the study were analysed. RESULTS: Twenty-one eyes of 21 patients met the inclusion criteria. Prior to the switch, the patients received a mean of 13.8 injections (median, 10; range, 3-39 injections) with the PRN regimen for 44 months (range, 3-100 months), which improved the visual acuity in five patients (24%). After a mean of 6.1 injections (median, 5; range, 3-14 injections) with the TAE regimen over 8 months (range, 2-16 months), the visual acuity improved in 12 patients (57%). The improvement in visual acuity during treatment with the TAE regimen was statistically significant (p = 0.005). The proportion of patients with a visual acuity of 0.2 or better was significantly higher after treatment with the TAE regimen than after treatment with the PRN regimen (p = 0.048). No significant differences in CRT were found between the two treatment regimens. CONCLUSION: Even after prolonged treatment and a high number of intravitreal injections, switching AMD patients from a PRN regimen to a strict TAE regimen significantly improves visual acuity. SN - 1755-3768 UR - https://www.unboundmedicine.com/medline/citation/28139082/Switching_from_pro_re_nata_to_treat_and_extend_regimen_improves_visual_acuity_in_patients_with_neovascular_age_related_macular_degeneration_ L2 - https://doi.org/10.1111/aos.13356 DB - PRIME DP - Unbound Medicine ER -